VJHemOnc is committed to improving our service to you

ASH 2019 | Should we adapt treatment based on MRD status in MM?

VJHemOnc is committed to improving our service to you

Graham Jackson

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK, discusses the question of whether we should adapt multiple myeloma (MM) treatment to the measurable residual disease (MRD) status of the patient. Prof. Jackson describes the difference between the US and Europe and highlights how there are no studies that validate stopping therapy according to MRD negativity. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter